読み込み中
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
前日終値
$1.02
+$0.02 · +2.00%
時間外
$1.074
+$0.054 · +5.29%
10月9日 19:16 ET
日中の時刻はETです。市場データは遅延する場合があります。
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
日中レンジ
現在 $1.02
52週レンジ
現在 $1.02
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
45
まちまち
リスク
57
やや高いリスク
モメンタム
40
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
日中レンジ
現在 $1.02
52週レンジ
現在 $1.02
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | 158万 USD | 968.5万 USD | 757.2万 USD |
| 売上原価 | 169.6万 USD | — | — | — | — |
| 粗利益 | −169.6万 USD | — | 158万 USD | 968.5万 USD | 757.2万 USD |
| 研究開発 | 1.09億 USD | 1.69億 USD | 1.28億 USD | 9693.6万 USD | 7754.9万 USD |
| 販売・一般管理 | 4721.6万 USD | 5905.5万 USD | 5792.8万 USD | 3994.9万 USD | 2755.8万 USD |
| 営業費用 | 1.48億 USD | 2.28億 USD | 1.86億 USD | 1.37億 USD | 1.05億 USD |
| 受取利息 | — | 2108.5万 USD | 2407.6万 USD | 467万 USD | 27.2万 USD |
| 支払利息 | 255.9万 USD | 302.4万 USD | 126.7万 USD | 79.1万 USD | — |
| 減価償却費と償却費 | 169.6万 USD | 212.5万 USD | 184.1万 USD | 182.3万 USD | 153.5万 USD |
| 営業利益 | −1.5億 USD | −2.28億 USD | −1.84億 USD | −1.27億 USD | −9753.5万 USD |
| 純利益 | −1.49億 USD | −2.1億 USD | −1.61億 USD | −1.23億 USD | −9726.3万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$25.86
上昇余地（2435.29%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI192.11万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF67.74万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC19.57万0.01%13.17億 USD0.60%$183+0.11%
Vanguard Health Care ETFVHT17.11万0.00%220億 USD0.09%$319.01+1.64%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM8万0.07%1.17億 USD0.73%$15.9402+0.25%
Invesco RAFI US 1500 Small-Mid ETFPRFZ2.17万0.00%26.52億 USD0.36%$53.16+0.64%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco RAFI US 1500 Small-Mid ETFPRFZAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
